Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI)
Makes specialty and rare disease medications for conditions like cancer, genetic disorders, and hormonal imbalances.
51.30-0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+1.2%
The outlook
Recordati trades at €51.30 with analyst consensus leaning toward Buy, and the average price target sits roughly 15% above the current level. The stock is positioned in the upper half of its 52-week range and trades above both its 50- and 200-day moving averages, reflecting a constructive near-term trend. At a trailing P/E of 22.8, the valuation reflects market expectations for the pharmaceutical company.
What’s behind the score
Analyst consensusBuy — 2.1 avg of 9 analysts
Price trendAbove its 50- & 200-day averages
52-week range66% of the way from its 52-week low to high
Price targetAvg target +15% vs current price
Analyst price target
~12-month · 9 analysts58.89average target+14.8% vs now
Now 51.30
Low 48.00High 71.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$10.44B
52-wk high
55.15
52-wk low
43.76
50-day avg
51.17
200-day avg
49.46
Trailing P/E
22.8